{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:40:00Z","timestamp":1793263200762,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10843-2","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T06:00:34Z","timestamp":1752818434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Deciphering TLR and JAK\/STAT pathways: genetic variants and targeted therapies in COVID-19"],"prefix":"10.1007","volume":"52","author":[{"given":"Meriem","family":"El Houdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4081-1604","authenticated-orcid":false,"given":"Hanaa","family":"Skhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Guennoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-5689","authenticated-orcid":false,"given":"Nadia","family":"Dakka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabii","family":"Ameziane El Hassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohra","family":"Ouzzif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1920-2310","authenticated-orcid":false,"given":"Jamila","family":"El Baghdadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"10843_CR1","doi-asserted-by":"publisher","first-page":"e51007","DOI":"10.2196\/51007","volume":"10","author":"Y Li","year":"2024","unstructured":"Li Y, Li J, Dang Y, Chen Y, Tao C (2024) Adverse events of COVID-19 vaccines in the united states: temporal and spatial analysis. JMIR Public Health Surveillance 10:e51007. https:\/\/doi.org\/10.2196\/51007","journal-title":"JMIR Public Health Surveillance"},{"key":"10843_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2024.12.003","volume":"82","author":"L Hiti","year":"2025","unstructured":"Hiti L, Markovi\u010d T, Lainscak M, Farka\u0161 Lain\u0161\u010dak J, Pal E, Mlinari\u010d-Ra\u0161\u010dan I (2025) The immunopathogenesis of a cytokine storm: the key mechanisms underlying severe COVID-19. Cytokine Growth Factor Rev 82:1\u201317. https:\/\/doi.org\/10.1016\/j.cytogfr.2024.12.003","journal-title":"Cytokine Growth Factor Rev"},{"key":"10843_CR3","doi-asserted-by":"publisher","unstructured":"Song Y, Lu J, Qin P, Chen H, Chen L Interferon-I modulation and natural products (2025) unraveling mechanisms and therapeutic potential in severe COVID-19. Cytokine Growth Factor Rev 82:18\u201330. https:\/\/doi.org\/10.1016\/j.cytogfr.2024.08.005","DOI":"10.1016\/j.cytogfr.2024.08.005"},{"key":"10843_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/bs.pmbts.2024.12.002","volume":"213","author":"K Lundstrom","year":"2025","unstructured":"Lundstrom K (2025) Immunobiology and immunotherapy of COVID-19. Prog Mol Biol Transl Sci 213:73\u2013133. https:\/\/doi.org\/10.1016\/bs.pmbts.2024.12.002","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"5","key":"10843_CR5","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1002\/jmv.26826","volume":"93","author":"S Khanmohammadi","year":"2021","unstructured":"Khanmohammadi S, Rezaei N (2021) Role of toll-like receptors in the pathogenesis of COVID-19. J Med Virol 93(5):2735\u20132739. https:\/\/doi.org\/10.1002\/jmv.26826","journal-title":"J Med Virol"},{"issue":"67","key":"10843_CR6","doi-asserted-by":"publisher","first-page":"eabm5505","DOI":"10.1126\/sciimmunol.abm5505","volume":"7","author":"SR Paludan","year":"2022","unstructured":"Paludan SR, Mogensen TH (2022) Innate immunological pathways in COVID-19 pathogenesis. Sci Immunol 7(67):eabm5505. https:\/\/doi.org\/10.1126\/sciimmunol.abm5505","journal-title":"Sci Immunol"},{"key":"10843_CR7","doi-asserted-by":"publisher","first-page":"115162","DOI":"10.1016\/j.bcp.2022.115162","volume":"202","author":"J Huang","year":"2022","unstructured":"Huang J, Zhou C, Deng J, Zhou J (2022) JAK inhibition as a new treatment strategy for patients with COVID-19. Biochem Pharmacol 202:115162. https:\/\/doi.org\/10.1016\/j.bcp.2022.115162","journal-title":"Biochem Pharmacol"},{"key":"10843_CR8","doi-asserted-by":"publisher","unstructured":"Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Ogishi M, Sabli IKD, Hodeib S, Korol C et al (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Sci (New York NY) 370(6515). https:\/\/doi.org\/10.1126\/science.abd4570","DOI":"10.1126\/science.abd4570"},{"issue":"17","key":"10843_CR9","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1016\/j.cell.2022.07.004","volume":"185","author":"JL Casanova","year":"2022","unstructured":"Casanova JL, Abel L (2022) From rare disorders of immunity to common determinants of infection: following the mechanistic thread. Cell 185(17):3086\u20133103. https:\/\/doi.org\/10.1016\/j.cell.2022.07.004","journal-title":"Cell"},{"issue":"7848","key":"10843_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-020-03065-y","volume":"591","author":"E Pairo-Castineira","year":"2021","unstructured":"Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S, Parkinson N, Fourman MH, Russell CD et al (2021) Genetic mechanisms of critical illness in COVID-19. Nature 591(7848):92\u201398. https:\/\/doi.org\/10.1038\/s41586-020-03065-y","journal-title":"Nature"},{"key":"10843_CR11","doi-asserted-by":"publisher","unstructured":"Mantovani S, Oliviero B, Varchetta S, Renieri A, Mondelli MU (2023) TLRs: innate immune sentries against SARS-CoV-2 infection. Int J Mol Sci 24(9). https:\/\/doi.org\/10.3390\/ijms24098065","DOI":"10.3390\/ijms24098065"},{"key":"10843_CR12","doi-asserted-by":"publisher","first-page":"199339","DOI":"10.1016\/j.virusres.2024.199339","volume":"342","author":"AFL Montenegro","year":"2024","unstructured":"Montenegro AFL, Clementino MAF, Yaochite JNU (2024) Type I interferon pathway genetic variants in severe COVID-19. Virus Res 342:199339. https:\/\/doi.org\/10.1016\/j.virusres.2024.199339","journal-title":"Virus Res"},{"key":"10843_CR13","doi-asserted-by":"publisher","unstructured":"Povysil G, Butler-Laporte G, Shang N, Wang C, Khan A, Alaamery M, Nakanishi T, Zhou S, Forgetta V, Eveleigh RJ et al (2021) Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19. J Clin Investig 131(14). https:\/\/doi.org\/10.1172\/jci147834","DOI":"10.1172\/jci147834"},{"issue":"1","key":"10843_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.24875\/AIDSRev.24000018","volume":"27","author":"EM Junainah","year":"2025","unstructured":"Junainah EM, Abd-El-Rahman AH, Alamin AA, Hassan KE, Elesawy BH, Elrashidy AH, Alhosary AA, Tufail-Chaudhary H, El-Kenawy AE, Bashir AF et al (2025) Immunopathology and therapeutic strategies for long COVID: mechanisms, manifestations, and clinical implications. AIDS Rev 27(1):25\u201332. https:\/\/doi.org\/10.24875\/AIDSRev.24000018","journal-title":"AIDS Rev"},{"key":"10843_CR15","doi-asserted-by":"publisher","first-page":"812774","DOI":"10.3389\/fimmu.2022.812774","volume":"13","author":"T Duan","year":"2022","unstructured":"Duan T, Du Y, Xing C, Wang HY, Wang RF (2022) Toll-like receptor signaling and its role in cell-mediated immunity. Front Immunol 13:812774. https:\/\/doi.org\/10.3389\/fimmu.2022.812774","journal-title":"Front Immunol"},{"key":"10843_CR16","doi-asserted-by":"publisher","unstructured":"Greene TT, Zuniga EI (2021) Type I interferon induction and exhaustion during viral infection: plasmacytoid dendritic cells and emerging COVID-19 findings. Viruses 13(9). https:\/\/doi.org\/10.3390\/v13091839","DOI":"10.3390\/v13091839"},{"issue":"10","key":"10843_CR17","doi-asserted-by":"publisher","first-page":"e109622","DOI":"10.15252\/embj.2021109622","volume":"41","author":"RM van der Sluis","year":"2022","unstructured":"van der Sluis RM, Cham LB, Gris-Oliver A, Gammelgaard KR, Pedersen JG, Idorn M, Ahmadov U, Hernandez SS, C\u00e9malovic E, Godsk SH et al (2022) TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS-CoV-2 infection. EMBO J 41(10):e109622. https:\/\/doi.org\/10.15252\/embj.2021109622","journal-title":"EMBO J"},{"issue":"7","key":"10843_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/s41590-021-00937-x","volume":"22","author":"M Zheng","year":"2021","unstructured":"Zheng M, Karki R, Williams EP, Yang D, Fitzpatrick E, Vogel P, Jonsson CB, Kanneganti TD (2021) TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol 22(7):829\u2013838. https:\/\/doi.org\/10.1038\/s41590-021-00937-x","journal-title":"Nat Immunol"},{"key":"10843_CR19","doi-asserted-by":"publisher","first-page":"106946","DOI":"10.1016\/j.vph.2021.106946","volume":"142","author":"TJ Costa","year":"2022","unstructured":"Costa TJ, Potje SR, Fraga-Silva TFC, da Silva-Neto JA, Barros PR, Rodrigues D, Machado MR, Martins RB, Santos-Eichler RA, Benatti MN et al (2022) Mitochondrial DNA and TLR9 activation contribute to SARS-CoV-2-induced endothelial cell damage. Vascul Pharmacol 142:106946. https:\/\/doi.org\/10.1016\/j.vph.2021.106946","journal-title":"Vascul Pharmacol"},{"key":"10843_CR20","doi-asserted-by":"publisher","first-page":"110498","DOI":"10.1016\/j.dib.2024.110498","volume":"54","author":"N Arefinia","year":"2024","unstructured":"Arefinia N, Banafi P, Zarezadeh MA, Mousawi HS, Yaghobi R, Farokhnia M, Sarvari J (2024) TLR3, TLR7, and TLR8 genes expression datasets in COVID-19 patients: influences of the disease severity and gender. Data Brief 54:110498. https:\/\/doi.org\/10.1016\/j.dib.2024.110498","journal-title":"Data Brief"},{"key":"10843_CR21","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.2147\/jir.S474707","volume":"17","author":"CN Asaba","year":"2024","unstructured":"Asaba CN, Ekabe CJ, Ayuk HS, Gwanyama BN, Bitazar R, Bukong TN (2024) Interplay of TLR4 and SARS-CoV-2: unveiling the complex mechanisms of inflammation and severity in COVID-19 infections. J Inflamm Res 17:5077\u20135091. https:\/\/doi.org\/10.2147\/jir.S474707","journal-title":"J Inflamm Res"},{"issue":"12","key":"10843_CR22","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.7150\/ijbs.72663","volume":"18","author":"W Wang","year":"2022","unstructured":"Wang W, Chen J, Yu X, Lan HY (2022) Signaling mechanisms of SARS-CoV-2 nucleocapsid protein in viral infection, cell death and inflammation. Int J Biol Sci 18(12):4704\u20134713. https:\/\/doi.org\/10.7150\/ijbs.72663","journal-title":"Int J Biol Sci"},{"key":"10843_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s41232-020-00146-3","volume":"40","author":"S Hojyo","year":"2020","unstructured":"Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, Hirano T (2020) How COVID-19 induces cytokine storm with high mortality. Inflamm Regeneration 40:37. https:\/\/doi.org\/10.1186\/s41232-020-00146-3","journal-title":"Inflamm Regeneration"},{"key":"10843_CR24","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3389\/fimmu.2020.01446","volume":"11","author":"D Ragab","year":"2020","unstructured":"Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R (2020) The COVID-19 cytokine storm; what we know so far. Front Immunol 11:1446. https:\/\/doi.org\/10.3389\/fimmu.2020.01446","journal-title":"Front Immunol"},{"issue":"1","key":"10843_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13054-022-04002-3","volume":"26","author":"C Loyer","year":"2022","unstructured":"Loyer C, Lapostolle A, Urbina T, Elabbadi A, Lavillegrand JR, Chaigneau T, Simoes C, Dessajan J, Desnos C, Morin-Brureau M et al (2022) Impairment of neutrophil functions and homeostasis in COVID-19 patients: association with disease severity. Crit Care (London England) 26(1):155. https:\/\/doi.org\/10.1186\/s13054-022-04002-3","journal-title":"Crit Care (London England)"},{"issue":"10","key":"10843_CR26","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","volume":"26","author":"DM Del Valle","year":"2020","unstructured":"Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A et al (2020) An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 26(10):1636\u20131643. https:\/\/doi.org\/10.1038\/s41591-020-1051-9","journal-title":"Nat Med"},{"issue":"1","key":"10843_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s10875-025-01892-0","volume":"45","author":"A Antol\u00ed","year":"2025","unstructured":"Antol\u00ed A, Vargas-Parra G, Sierra-Fortuny A, Gomez-Vazquez JL, Rofes P, Munt\u00e9 E, Viana-Errasti J, Mar\u00edn-Montes R, L\u00f3pez-Doriga A, Feliubadal\u00f3 L et al (2025) From rare to common: genetic insights into TLR7 variants in a multicentric Spanish study on COVID-19 severity. J Clin Immunol 45(1):100. https:\/\/doi.org\/10.1007\/s10875-025-01892-0","journal-title":"J Clin Immunol"},{"issue":"S6","key":"10843_CR28","doi-asserted-by":"publisher","first-page":"9216","DOI":"10.53730\/ijhs.v6nS6.12425","volume":"6","author":"SA Hussein","year":"2022","unstructured":"Hussein SA, Mohammed HQ, Mohammed HA (2022) Exploring the significant role of TLR 7 gene polymorphism with severity infection of COVID-19 patients in Wasit Province. Int J Health Sci 6(S6):9216\u20139225. https:\/\/doi.org\/10.53730\/ijhs.v6nS6.12425","journal-title":"Int J Health Sci"},{"key":"10843_CR29","doi-asserted-by":"publisher","first-page":"108929","DOI":"10.1016\/j.clim.2022.108929","volume":"235","author":"MM Alseoudy","year":"2022","unstructured":"Alseoudy MM, Elgamal M, Abdelghany DA, Borg AM, El-Mesery A, Elzeiny D, Hammad MO (2022) Prognostic impact of toll-like receptors gene polymorphism on outcome of COVID-19 pneumonia: a case-control study. Clin Immunol (Orlando Fla) 235:108929. https:\/\/doi.org\/10.1016\/j.clim.2022.108929","journal-title":"Clin Immunol (Orlando Fla)"},{"issue":"3","key":"10843_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7883\/yoken.JJID.2023.411","volume":"77","author":"B Bayyurt","year":"2024","unstructured":"Bayyurt B, Baltac\u0131 S, \u015eahin N, Arslan S, Bak\u0131r M (2024) Relationship of Toll-Like receptor 7, 9, and 10 polymorphisms and the severity of coronavirus disease 2019. Jpn J Infect Dis 77(3):161\u2013168. https:\/\/doi.org\/10.7883\/yoken.JJID.2023.411","journal-title":"Jpn J Infect Dis"},{"issue":"3","key":"10843_CR31","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10875-022-01215-7","volume":"42","author":"H Abolhassani","year":"2022","unstructured":"Abolhassani H, Landegren N, Bastard P, Materna M, Modaresi M, Du L, Aranda-Guill\u00e9n M, Sardh F, Zuo F, Zhang P et al (2022) Inherited IFNAR1 deficiency in a child with both critical COVID-19 pneumonia and multisystem inflammatory syndrome. J Clin Immunol 42(3):471\u2013483. https:\/\/doi.org\/10.1007\/s10875-022-01215-7","journal-title":"J Clin Immunol"},{"issue":"7","key":"10843_CR32","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/jama.2020.13719","volume":"324","author":"CI van der Made","year":"2020","unstructured":"van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S, van Deuren RC, Steehouwer M, van Reijmersdal SV, Jaeger M et al (2020) Presence of genetic variants among young men with severe COVID-19. JAMA 324(7):663\u2013673. https:\/\/doi.org\/10.1001\/jama.2020.13719","journal-title":"JAMA"},{"key":"10843_CR33","doi-asserted-by":"publisher","unstructured":"Asano T, Boisson B, Onodi F, Matuozzo D, Moncada-Velez M, Maglorius Renkilaraj MRL, Zhang P, Meertens L, Bolze A, Materna M et al (2021) X-linked recessive TLR7 deficiency in ~\u20091% of men under 60 years old with life-threatening COVID-19. Sci Immunol 6(62). https:\/\/doi.org\/10.1126\/sciimmunol.abl4348","DOI":"10.1126\/sciimmunol.abl4348"},{"key":"10843_CR34","doi-asserted-by":"publisher","unstructured":"Fallerini C, Daga S, Mantovani S, Benetti E, Picchiotti N, Francisci D, Paciosi F, Schiaroli E, Baldassarri M, Fava F et al (2021) Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. eLife 10. https:\/\/doi.org\/10.7554\/eLife.67569","DOI":"10.7554\/eLife.67569"},{"key":"10843_CR35","doi-asserted-by":"publisher","first-page":"719115","DOI":"10.3389\/fimmu.2021.719115","volume":"12","author":"X Solanich","year":"2021","unstructured":"Solanich X, Vargas-Parra G, van der Made CI, Simons A, Schuurs-Hoeijmakers J, Antol\u00ed A, Del Valle J, Rocamora-Blanch G, Seti\u00e9n F, Esteller M et al (2021) Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19. Front Immunol 12:719115. https:\/\/doi.org\/10.3389\/fimmu.2021.719115","journal-title":"Front Immunol"},{"key":"10843_CR36","doi-asserted-by":"publisher","unstructured":"Zhang Q, Matuozzo D, Le Pen J, Lee D, Moens L, Asano T, Bohlen J, Liu Z, Moncada-Velez M, Kendir-Demirkol Y et al (2022) Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. J Exp Med 219(8). https:\/\/doi.org\/10.1084\/jem.20220131","DOI":"10.1084\/jem.20220131"},{"issue":"2","key":"10843_CR37","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s10875-021-01172-7","volume":"42","author":"G Bucciol","year":"2022","unstructured":"Bucciol G, Desmet L, Corveleyn A, Meyts I (2022) Pathogenic P554S variant in TLR3 in a patient with severe influenza pneumonia. J Clin Immunol 42(2):430\u2013432. https:\/\/doi.org\/10.1007\/s10875-021-01172-7","journal-title":"J Clin Immunol"},{"issue":"7","key":"10843_CR38","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1080\/15548627.2021.1995152","volume":"18","author":"S Croci","year":"2022","unstructured":"Croci S, Venneri MA, Mantovani S, Fallerini C, Benetti E, Picchiotti N, Campolo F, Imperatore F, Palmieri M, Daga S et al (2022) The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males. Autophagy 18(7):1662\u20131672. https:\/\/doi.org\/10.1080\/15548627.2021.1995152","journal-title":"Autophagy"},{"issue":"24","key":"10843_CR39","doi-asserted-by":"publisher","first-page":"17696","DOI":"10.1074\/jbc.M700209200","volume":"282","author":"CT Ranjith-Kumar","year":"2007","unstructured":"Ranjith-Kumar CT, Miller W, Sun J, Xiong J, Santos J, Yarbrough I, Lamb RJ, Mills J, Duffy KE, Hoose S et al (2007) Effects of single nucleotide polymorphisms on toll-like receptor 3 activity and expression in cultured cells. J Biol Chem 282(24):17696\u201317705. https:\/\/doi.org\/10.1074\/jbc.M700209200","journal-title":"J Biol Chem"},{"issue":"5","key":"10843_CR40","doi-asserted-by":"publisher","first-page":"e2214985","DOI":"10.1001\/jamanetworkopen.2022.14985","volume":"5","author":"W Abuhammour","year":"2022","unstructured":"Abuhammour W, Yavuz L, Jain R, Abu Hammour K, Al-Hammouri GF, El Naofal M, Halabi N, Yaslam S, Ramaswamy S, Taylor A et al (2022) Genetic and clinical characteristics of patients in the Middle East with multisystem inflammatory syndrome in children. JAMA Netw Open 5(5):e2214985. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.14985","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10843_CR41","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1164\/rccm.200807-1020OC","volume":"178","author":"LA Murray","year":"2008","unstructured":"Murray LA, Knight DA, McAlonan L, Argentieri R, Joshi A, Shaheen F, Cunningham M, Alexopolou L, Flavell RA, Sarisky RT et al (2008) Deleterious role of TLR3 during hyperoxia-induced acute lung injury. Am J Respir Crit Care Med 178(12):1227\u20131237. https:\/\/doi.org\/10.1164\/rccm.200807-1020OC","journal-title":"Am J Respir Crit Care Med"},{"key":"10843_CR42","doi-asserted-by":"publisher","unstructured":"Suarez-Pajes E, Tosco-Herrera E, Ramirez-Falcon M, Gonzalez-Barbuzano S, Hernandez-Beeftink T, Guillen-Guio B, Villar J, Flores C (2023) Genetic determinants of the acute respiratory distress syndrome. J Clin Med 12(11). https:\/\/doi.org\/10.3390\/jcm12113713","DOI":"10.3390\/jcm12113713"},{"key":"10843_CR43","doi-asserted-by":"publisher","unstructured":"Zhang H, Li H, Watowich SS (2016) Jak-STAT signaling pathways. In: activation of the immune system. Elsevier Inc 134\u2013145. https:\/\/doi.org\/10.1016\/B978-0-12-374279-7.11015-X","DOI":"10.1016\/B978-0-12-374279-7.11015-X"},{"issue":"1","key":"10843_CR44","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, Bao Z, Lu J, Li L (2023) Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Therapy 8(1):204. https:\/\/doi.org\/10.1038\/s41392-023-01468-7","journal-title":"Signal Transduct Target Therapy"},{"key":"10843_CR45","doi-asserted-by":"publisher","first-page":"606874","DOI":"10.3389\/fimmu.2020.606874","volume":"11","author":"LE Fox","year":"2020","unstructured":"Fox LE, Locke MC, Lenschow DJ (2020) Context is key: delineating the unique functions of IFN\u03b1 and IFN\u03b2 in disease. Front Immunol 11:606874. https:\/\/doi.org\/10.3389\/fimmu.2020.606874","journal-title":"Front Immunol"},{"issue":"3","key":"10843_CR46","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1002\/mco2.254","volume":"4","author":"Y Xue","year":"2023","unstructured":"Xue Y, Mei H, Chen Y, Griffin JD, Liu Q, Weisberg E, Yang J (2023) Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV\u20102. MedComm 4(3):e254. https:\/\/doi.org\/10.1002\/mco2.254","journal-title":"MedComm"},{"issue":"1","key":"10843_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10875-021-01166-5","volume":"42","author":"S Khanmohammadi","year":"2022","unstructured":"Khanmohammadi S, Rezaei N, Khazaei M, Shirkani A (2022) A case of autosomal recessive interferon alpha\/beta receptor alpha chain (IFNAR1) deficiency with severe COVID-19. J Clin Immunol 42(1):19\u201324. https:\/\/doi.org\/10.1007\/s10875-021-01166-5","journal-title":"J Clin Immunol"},{"key":"10843_CR48","doi-asserted-by":"publisher","first-page":"1523627","DOI":"10.3389\/fped.2025.1523627","volume":"13","author":"K Kozak","year":"2025","unstructured":"Kozak K, Pavlyshyn H, Kamyshnyi O, Shevchuk O, Korda M, Vari SG (2025) The influence of genetic polymorphisms on cytokine profiles in pediatric COVID-19: a pilot study. Front Pead 13:1523627. https:\/\/doi.org\/10.3389\/fped.2025.1523627","journal-title":"Front Pead"},{"issue":"7889","key":"10843_CR49","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/s41586-021-03767-x","volume":"600","author":"COVID-19 Host Genetics Initiative","year":"2021","unstructured":"COVID-19 Host Genetics Initiative (2021) Mapping the human genetic architecture of COVID-19. Nature 600(7889):472\u2013477. https:\/\/doi.org\/10.1038\/s41586-021-03767-x","journal-title":"Nature"},{"issue":"1","key":"10843_CR50","doi-asserted-by":"publisher","first-page":"20728","DOI":"10.1038\/s41598-024-71476-2","volume":"14","author":"P Delgado-Wicke","year":"2024","unstructured":"Delgado-Wicke P, Fern\u00e1ndez de C\u00f3rdoba-O\u00f1ate S, Roy-Vallejo E, Alegr\u00eda-Carrasco E, Rodr\u00edguez-Serrano DA, Lamana A, Montes N, Nicolao-G\u00f3mez A, Carracedo-Rodr\u00edguez R, Marcos-Jim\u00e9nez A et al (2024) Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables. Sci Rep 14(1):20728. https:\/\/doi.org\/10.1038\/s41598-024-71476-2","journal-title":"Sci Rep"},{"key":"10843_CR51","doi-asserted-by":"publisher","unstructured":"Wu D, Yang XO TH17 responses in cytokine storm of COVID-19 (2020) an emerging target of JAK2 inhibitor fedratinib. J Microbiol Immunol Infect 53(3):368\u2013370. https:\/\/doi.org\/10.1016\/j.jmii.2020.03.005","DOI":"10.1016\/j.jmii.2020.03.005"},{"key":"10843_CR52","doi-asserted-by":"publisher","unstructured":"Levy G, Guglielmelli P, Langmuir P, Constantinescu SN (2022) JAK inhibitors and COVID-19. J Immunother Cancer 10(4). https:\/\/doi.org\/10.1136\/jitc-2021-002838","DOI":"10.1136\/jitc-2021-002838"},{"issue":"2","key":"10843_CR53","doi-asserted-by":"publisher","first-page":"e13898","DOI":"10.1111\/eci.13898","volume":"53","author":"A Ferrarini","year":"2023","unstructured":"Ferrarini A, Vacca A, Solimando AG, Tavio M, Acquaviva R, Rocchi M, Nitti C, Salvi A, Menditto V, Luchetti Gentiloni MM et al (2023) Early administration of tofacitinib in COVID-19 pneumonitis: an open randomised controlled trial. Eur J Clin Invest 53(2):e13898. https:\/\/doi.org\/10.1111\/eci.13898","journal-title":"Eur J Clin Invest"},{"key":"10843_CR54","doi-asserted-by":"publisher","first-page":"108517","DOI":"10.1016\/j.clim.2020.108517","volume":"218","author":"S Yeleswaram","year":"2020","unstructured":"Yeleswaram S, Smith P, Burn T, Covington M, Juvekar A, Li Y, Squier P, Langmuir P (2020) Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment. Clin Immunol (Orlando Fla) 218:108517. https:\/\/doi.org\/10.1016\/j.clim.2020.108517","journal-title":"Clin Immunol (Orlando Fla)"},{"issue":"9","key":"10843_CR55","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/s41375-023-01979-w","volume":"37","author":"J Hammersen","year":"2023","unstructured":"Hammersen J, Birndt S, D\u00f6hner K, Reuken P, Stallmach A, Sauerbrey P, La Ros\u00e9e F, Pfirrmann M, Fabisch C, Weiss M et al (2023) The JAK1\/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial. Leukemia 37(9):1879\u20131886. https:\/\/doi.org\/10.1038\/s41375-023-01979-w","journal-title":"Leukemia"},{"issue":"7","key":"10843_CR56","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","volume":"34","author":"F La Ros\u00e9e","year":"2020","unstructured":"La Ros\u00e9e F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, Fellhauer M, Henkes M, Kumle B, Russo SG et al (2020) The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia 34(7):1805\u20131815. https:\/\/doi.org\/10.1038\/s41375-020-0891-0","journal-title":"Leukemia"},{"issue":"3","key":"10843_CR57","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3947\/ic.2020.0126","volume":"53","author":"JR Quiros","year":"2021","unstructured":"Quiros JR, Ross-Comptis J, Hathaway D 3rd, Sarfraz A, Sarfraz Z, Grigoryan Z, Romero KA, Gapizov A, Pr\u00edncipe-Meneses FS, Somagutta MR et al (2021) Ruxolitinib and the mitigation of severe COVID-19: a systematic review and meta-analysis. Infect Chemother 53(3):436\u2013448. https:\/\/doi.org\/10.3947\/ic.2020.0126","journal-title":"Infect Chemother"},{"issue":"18","key":"10843_CR58","doi-asserted-by":"publisher","first-page":"e106275","DOI":"10.15252\/embj.2020106275","volume":"39","author":"T Klemm","year":"2020","unstructured":"Klemm T, Ebert G, Calleja DJ, Allison CC, Richardson LW, Bernardini JP, Lu BG, Kuchel NW, Grohmann C, Shibata Y et al (2020) Mechanism and inhibition of the papain-like protease, plpro, of SARS-CoV-2. EMBO J 39(18):e106275. https:\/\/doi.org\/10.15252\/embj.2020106275","journal-title":"EMBO J"},{"issue":"2","key":"10843_CR59","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","volume":"81","author":"F Cantini","year":"2020","unstructured":"Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D (2020) Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect 81(2):318\u2013356. https:\/\/doi.org\/10.1016\/j.jinf.2020.04.017","journal-title":"J Infect"},{"key":"10843_CR60","doi-asserted-by":"publisher","unstructured":"Stebbing J, S\u00e1nchez Nievas G, Falcone M, Youhanna S, Richardson P, Ottaviani S, Shen JX, Sommerauer C, Tiseo G, Ghiadoni L et al (2021) JAK Inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv 7(1). https:\/\/doi.org\/10.1126\/sciadv.abe4724","DOI":"10.1126\/sciadv.abe4724"},{"issue":"19","key":"10843_CR61","doi-asserted-by":"publisher","first-page":"e38229","DOI":"10.1016\/j.heliyon.2024.e38229","volume":"10","author":"G Wilar","year":"2024","unstructured":"Wilar G, Suhandi C, Fukunaga K, Kawahata I (2024) Efficacy and safety of tofacitinib on COVID-19 patients: a systematic review and meta-analysis. Heliyon 10(19):e38229. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38229","journal-title":"Heliyon"},{"issue":"9","key":"10843_CR62","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S et al (2021) Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 384(9):795\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa2031994","journal-title":"N Engl J Med"},{"issue":"6","key":"10843_CR63","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/s1473-3099(22)00873-8","volume":"23","author":"CKH Wong","year":"2023","unstructured":"Wong CKH, Lau KTK, Au ICH, Lau EHY, Poon LLM, Hung IFN, Cowling BJ, Leung GM (2023) Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study. Lancet Infect Dis 23(6):683\u2013695. https:\/\/doi.org\/10.1016\/s1473-3099(22)00873-8","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10843_CR64","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccm.2008.06.007","volume":"29","author":"SP LaRosa","year":"2008","unstructured":"LaRosa SP, Opal SM (2008) Sepsis strategies in development. Clin Chest Med 29(4):735\u2013747, x-xi. https:\/\/doi.org\/10.1016\/j.ccm.2008.06.007","journal-title":"Clin Chest Med"},{"issue":"1 Suppl","key":"10843_CR65","doi-asserted-by":"publisher","first-page":"I270","DOI":"10.1161\/circulationaha.105.000901","volume":"114","author":"A Shimamoto","year":"2006","unstructured":"Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, Agnew ML, Hampton CR, Rothnie CL, Spring DJ et al (2006) Inhibition of Toll-like receptor 4 with Eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 114(1 Suppl):I270\u2013274. https:\/\/doi.org\/10.1161\/circulationaha.105.000901","journal-title":"Circulation"},{"key":"10843_CR66","doi-asserted-by":"publisher","first-page":"8874339","DOI":"10.1155\/2021\/8874339","volume":"2021","author":"MM Aboudounya","year":"2021","unstructured":"Aboudounya MM, Heads RJ (2021) COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation. Mediat Inflamm 2021:8874339. https:\/\/doi.org\/10.1155\/2021\/8874339","journal-title":"Mediat Inflamm"},{"issue":"11","key":"10843_CR67","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1001\/jama.2013.2194","volume":"309","author":"SM Opal","year":"2013","unstructured":"Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M et al (2013) Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 309(11):1154\u20131162. https:\/\/doi.org\/10.1001\/jama.2013.2194","journal-title":"JAMA"},{"issue":"1","key":"10843_CR68","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1124\/mol.110.068064","volume":"79","author":"N Matsunaga","year":"2011","unstructured":"Matsunaga N, Tsuchimori N, Matsumoto T, Ii M (2011) TAK-242 (resatorvid), a small-molecule inhibitor of toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol 79(1):34\u201341. https:\/\/doi.org\/10.1124\/mol.110.068064","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10843_CR69","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13075-020-2097-2","volume":"22","author":"S Samarpita","year":"2020","unstructured":"Samarpita S, Kim JY, Rasool MK, Kim KS (2020) Investigation of toll-like receptor (TLR) 4 inhibitor TAK-242 as a new potential anti-rheumatoid arthritis drug. Arthritis Res Therapy 22(1):16. https:\/\/doi.org\/10.1186\/s13075-020-2097-2","journal-title":"Arthritis Res Therapy"},{"issue":"1","key":"10843_CR70","doi-asserted-by":"publisher","first-page":"2313176","DOI":"10.1080\/0886022x.2024.2313176","volume":"46","author":"YM Xia","year":"2024","unstructured":"Xia YM, Guan YQ, Liang JF, Wu WD (2024) TAK-242 improves sepsis-associated acute kidney injury in rats by inhibiting the TLR4\/NF-\u03baB signaling pathway. Ren Fail 46(1):2313176. https:\/\/doi.org\/10.1080\/0886022x.2024.2313176","journal-title":"Ren Fail"},{"key":"10843_CR71","doi-asserted-by":"publisher","unstructured":"Aboudounya MM, Holt MR, Heads RJ (2021) SARS-CoV-2 Spike S1 glycoprotein is a TLR4 agonist, upregulates ACE2 expression and induces pro-inflammatory M1 macrophage polarisation. BioRxiv 202120082011455921. https:\/\/doi.org\/10.1101\/2021.08.11.455921","DOI":"10.1101\/2021.08.11.455921"},{"issue":"7","key":"10843_CR72","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41422-021-00495-9","volume":"31","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Kuang M, Li J, Zhu L, Jia Z, Guo X, Hu Y, Kong J, Yin H, Wang X et al (2021) SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res 31(7):818\u2013820. https:\/\/doi.org\/10.1038\/s41422-021-00495-9","journal-title":"Cell Res"},{"issue":"3","key":"10843_CR73","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.120.000275","volume":"376","author":"J Vlach","year":"2021","unstructured":"Vlach J, Bender AT, Przetak M, Pereira A, Deshpande A, Johnson TL, Reissig S, Tzvetkov E, Musil D, Morse NT et al (2021) Discovery of M5049: a novel selective toll-like receptor 7\/8 inhibitor for treatment of autoimmunity. J Pharmacol Exp Ther 376(3):397\u2013409. https:\/\/doi.org\/10.1124\/jpet.120.000275","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10843_CR74","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1111\/cts.13658","volume":"16","author":"JE McKinnon","year":"2023","unstructured":"McKinnon JE, Santiaguel J, Murta de Oliveira C, Yu D, Khursheed M, Moreau F, Klopp-Schulze L, Shaw J, Roy S, Kao AH (2023) Enpatoran in COVID-19 pneumonia: safety and efficacy results from a phase II randomized trial. Clin Transl Sci 16(12):2640\u20132653. https:\/\/doi.org\/10.1111\/cts.13658","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10843_CR75","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/s41467-024-46490-7","volume":"15","author":"D Planas","year":"2024","unstructured":"Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, Porrot F, Guivel-Benhassine F, Jeyarajah B, Brisebarre A et al (2024) Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion. Nat Commun 15(1):2254. https:\/\/doi.org\/10.1038\/s41467-024-46490-7","journal-title":"Nat Commun"},{"issue":"1","key":"10843_CR76","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/s41467-024-45075-8","volume":"15","author":"G Shi","year":"2024","unstructured":"Shi G, Li T, Lai KK, Johnson RF, Yewdell JW, Compton AA (2024) Omicron spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue. Nat Commun 15(1):889. https:\/\/doi.org\/10.1038\/s41467-024-45075-8","journal-title":"Nat Commun"},{"key":"10843_CR77","doi-asserted-by":"publisher","first-page":"1207225","DOI":"10.3389\/fcimb.2023.1207225","volume":"13","author":"W Guo","year":"2023","unstructured":"Guo W, Zheng Y, Feng S (2023) Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes. Front Cell Infect Microbiol 13:1207225. https:\/\/doi.org\/10.3389\/fcimb.2023.1207225","journal-title":"Front Cell Infect Microbiol"},{"key":"10843_CR78","doi-asserted-by":"publisher","first-page":"199509","DOI":"10.1016\/j.virusres.2024.199509","volume":"351","author":"M El Houdi","year":"2025","unstructured":"El Houdi M, Skhoun H, El Fessikh M, Benmansour R, El Yousfi FZ, Nebhani C, Tagajdid MR, Lahlou Amine I, El Annaz H, El Ameziane R et al (2025) Association study of the JAK\/STAT signaling pathway with susceptibility to COVID-19 in Moroccan patient and in-silico analysis of rare variants. Virus Res 351:199509. https:\/\/doi.org\/10.1016\/j.virusres.2024.199509","journal-title":"Virus Res"},{"key":"10843_CR79","doi-asserted-by":"publisher","unstructured":"Abdelhafez M, Nasereddin A, Shamma OA, Abed R, Sinnokrot R, Marof O, Heif T, Erekat Z, Al-Jawabreh A, Ereqat S (2023) Association of IFNAR2 rs2236757 and OAS3 rs10735079 polymorphisms with susceptibility to COVID-19 infection and severity in Palestine. https:\/\/doi.org\/10.1155\/2023\/9551163. Interdisciplinary perspectives on infectious diseases 2023:9551163","DOI":"10.1155\/2023\/9551163"},{"issue":"1","key":"10843_CR80","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13054-023-04388-8","volume":"27","author":"J Jalkanen","year":"2023","unstructured":"Jalkanen J, Khan S, Elima K, Huttunen T, Wang N, Hollm\u00e9n M, Elo LL, Jalkanen S (2023) Polymorphism in interferon alpha\/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19. Critical care. (London England) 27(1):112. https:\/\/doi.org\/10.1186\/s13054-023-04388-8","journal-title":"(London England)"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10843-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10843-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10843-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T04:26:41Z","timestamp":1766896001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10843-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10843"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10843-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"733"}}